89Bio Inc
ETNB
Detailliertes Diagramm anzeigen
14.840USD
0.000
Handelsschluss 11/11, 16:00（ET）Kurse um 15 Minuten verzögert
2.20BMarktkapitalisierung
VerlustKGV TTM
Intraday
1m
30m
1h
D
W
M
D
Heute
0.00%
5 Tage
0.00%
1 Monat
+0.27%
6 Monate
+92.73%
Seit Jahresbeginn
+89.77%
1 Jahr
+42.01%
Detailliertes Diagramm anzeigen
TradingKey Aktienbewertung von 89Bio Inc
Währung: USD Aktualisiert: 2025-10-27Wichtige Einblicke
Seine Bewertung wird als unterbewertet angesehen,und die institutionelle Anerkennung ist sehr hoch. In den letzten 30 Tagen haben mehrere Analysten die Aktie mit einer Kaufen bewertet. Der Aktienkurs bewegt sich seitwärts zwischen den Unterstützungs- und Widerstandsniveaus, was ihn für schwankungsorientiertes Trading geeignet macht.
89Bio Inc Bewertung
Widerstand & Unterstützung
Keine Daten
Radar Chart
Aktueller Preis
Vorher
Analysten-Ziel
Basierend auf insgesamt
0
Analysten
--
Aktuelles Rating
26.917
Kursziel
+81.38%
Aufwärtspotenzial
Hinweis: Analystenbewertungen und Kursziele werden von LSEG ausschließlich zu Informationszwecken bereitgestellt und stellen keine Anlageberatung dar.
89Bio Inc Highlights
HöhepunkteRisiko
89bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The Company’s lead product candidate, pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG). Pegozafermin is engineered to protect against proteolysis and reduce renal clearance and optimize its potency, enabling the potential use of a lower dosage/dose. Pegozafermin has been optimally constructed with two mutations via substitutions with natural amino acids at site-specific positions (173 and 176) toward the C-terminus end of the hormone. It conducted a Phase I clinical trial to evaluate the safety, tolerability and pharmacokinetics (PK) of pegozafermin.
high_profit_growth
high_profit_growth_desc%!(EXTRA string=0.00)
valuation_underestimated
valuation_underestimated_desc%!(EXTRA string=PE, string=-4.02)
institutional_decreasing_position
institutional_decreasing_position_desc%!(EXTRA string=154.05M, string=12.61%)
institutional_hold%!(EXTRA string=Steven Cohen)
institutional_hold_desc%!(EXTRA string=Steven Cohen, string=2.27M)
89Bio Inc Nachrichten
Bald gibt es mehr Neuigkeiten, bleiben Sie dran...
Finanzindikatoren
EPS
Keine Daten
Gesamteinnahmen
Keine Daten
89Bio Inc Informationen
89bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The Company’s lead product candidate, pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG). Pegozafermin is engineered to protect against proteolysis and reduce renal clearance and optimize its potency, enabling the potential use of a lower dosage/dose. Pegozafermin has been optimally constructed with two mutations via substitutions with natural amino acids at site-specific positions (173 and 176) toward the C-terminus end of the hormone. It conducted a Phase I clinical trial to evaluate the safety, tolerability and pharmacokinetics (PK) of pegozafermin.
BörsenkürzelETNB
Unternehmen89Bio Inc
CEOMr. Rohan Palekar
Websitehttps://www.89bio.com/
Verwandte Finanzinstrumente
+2.27%
+2.88%
+2.98%
+1.84%
+2.59%
+4.84%
+4.57%
+6.99%
+3.73%
+4.57%
+2.03%
+1.90%
-0.31%
+3.08%
+2.26%
+3.08%
0.00%
+3.03%
+2.32%
+2.28%Beliebte Symbole
